Hiroto Ohguchi

Kumamoto, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications

IL-6-driven POU2AF1 and ELL2 are key regulators of multiple myeloma-distinct transcriptional and splicing programs.

IL-6-driven POU2AF1 and ELL2 are key regulators of multiple myeloma-distinct transcriptional and splicing programs.

Journal: Blood advances
Published: October 10, 2025

Epigenetic dysregulation driving multiple myeloma

Epigenetic dysregulation driving multiple myeloma

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: August 06, 2025

Protocol for transcriptomic and epigenomic analyses of tip-like endothelial cells using scRNA-seq and ChIP-seq.

Protocol for transcriptomic and epigenomic analyses of tip-like endothelial cells using scRNA-seq and ChIP-seq.

Journal: STAR protocols
Published: May 27, 2024

Increased CSN5 expression enhances the sensitivity to lenalidomide in multiple myeloma cells.

Increased CSN5 expression enhances the sensitivity to lenalidomide in multiple myeloma cells.

Journal: iScience
Published: March 27, 2024

Multiple myeloma-associated DIS3 gene is essential for hematopoiesis, but loss of DIS3 is insufficient for myelomagenesis.

Multiple myeloma-associated DIS3 gene is essential for hematopoiesis, but loss of DIS3 is insufficient for myelomagenesis.

Journal: Blood neoplasia
Published: November 29, 2023

DIS3: The Enigmatic Gene in Multiple Myeloma.

DIS3: The Enigmatic Gene in Multiple Myeloma.

Journal: International journal of molecular sciences
Published: January 16, 2023

FOXO1 stimulates tip cell-enriched gene expression in endothelial cells.

FOXO1 stimulates tip cell-enriched gene expression in endothelial cells.

Journal: iScience
Published: January 05, 2023

Diverse Functions of KDM5 in Cancer: Transcriptional Repressor or Activator?

Diverse Functions of KDM5 in Cancer: Transcriptional Repressor or Activator?

Journal: Cancers
Published: June 04, 2022

Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase.

Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase.

Journal: Blood advances
Published: January 26, 2022

Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications.

Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications.

Journal: Blood cancer journal
Published: October 07, 2021

Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma.

Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma.

Journal: Blood cancer discovery
Published: July 14, 2021

Inflammation-driven senescence-associated secretory phenotype in cancer-associated fibroblasts enhances peritoneal dissemination.

Inflammation-driven senescence-associated secretory phenotype in cancer-associated fibroblasts enhances peritoneal dissemination.

Journal: Cell reports
Published: May 29, 2020
Showing 1-12 of 35

Last Updated: 09/26/2026